Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 575

Sort by

Sort Order Select

Journal Articles

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

Blood (2025) 146 (25): 3050–3058.

https://doi.org/10.1182/blood.2025030084

Published: 2025

Includes: Supplemental data

Journal Articles

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load

Blood blood.2025030083.

https://doi.org/10.1182/blood.2025030083

Published: 2025

Includes: Supplemental data

Journal Articles

A T-cell–based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy

Wassilis S. C. Bruins, Febe Smits, Carolien Duetz, Kaz Groen, Charlotte L. B. M. Korst, A. Vera de Jonge, Christie P. M. Verkleij, Rosa Rentenaar, Meliha Cosovic, Merve Eken, Inoka Twickler, Paola M. Homan-Weert, Pieter Sonneveld, Philippe Moreau, Jürgen Claesen, Niels W. C. J. van de Donk, Sonja Zweegman, Tuna Mutis

Blood (2025) 146 (21): 2517–2530.

https://doi.org/10.1182/blood.2025028587

Published: 2025

Includes: Supplemental data

Journal Articles

A comparison between subcutaneous isa-vrd from the isasocut study and intravenous isa-vrd from the imroz study in patients with transplant- ineligible newly diagnosed multiple myeloma

Arthur Bobin, Mohamad Mohty, Philippe Moreau, Hartmut Goldschmidt, Meletios Dimopoulos, Robert Orlowski, Cyrille Touzeau, Aurore Perrot, Thomas Chalopin, Mamoun Dib, Lydia Montes, Umer Khan, Mony Morisse, Rick Zhang, Corina Oprea, Florence Suzan Teisserenc, Thierry Facon, Xavier Leleu

Blood (2025) 146 (Supplement 1): 7566.

https://doi.org/10.1182/blood-2025-7566

Published: 2025

Journal Articles

Relative mortality in elderly frail patients with newly diagnosed multiple myeloma: Ad-hoc analysis of the Phase 3 IFM 2017-03 trial compared to population-based data in France and implications for the functional cure concept

Julie Castiaux, Noemie Bigot, Cyrille Hulin, Magaret Macro, Kamel Laribi, Carla Araujo, Gian Matteo Pica, Cyrille Touzeau, Pascal Godmer, Aurore Perrot, Jean-Yves Mary, Jill Corre, Herve Avet-Loiseau, Philippe Moreau, Xavier Leleu, Thierry Facon, Jerome Lambert, Salomon Manier

Blood (2025) 146 (Supplement 1): 498.

https://doi.org/10.1182/blood-2025-498

Published: 2025

Journal Articles

Longitudinal assessments of minimal residual disease in high-risk patients from benefit phase 3 randomized Study of isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isard in newly diagnosed transplant ineligible multiple myeloma. (IFM 2020-05)

Blood (2025) 146 (Supplement 1): 497.

https://doi.org/10.1182/blood-2025-497

Published: 2025

Journal Articles

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

Blood (2025) 146 (Supplement 1): 494.

https://doi.org/10.1182/blood-2025-494

Published: 2025

Journal Articles

First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.

Blood (2025) 146 (Supplement 1): 5836.

https://doi.org/10.1182/blood-2025-5836

Published: 2025

Journal Articles

Apixaban pharmacokinetics in newly diagnosed multiple myeloma patients treated in the benefit and isasocut clinical trials: The apixabor/mibapix study

Blood (2025) 146 (Supplement 1): 744.

https://doi.org/10.1182/blood-2025-744

Published: 2025

Journal Articles

Single-cell immune landscape associated with isatuximab, carfilzomib, lenalidomide, and dexamethasone induction efficacy in newly diagnosed myeloma

Mael Penissat-mahaut, Pierre-Paul Axisa, Hélène Daunes, Marine Cuisinier, Marie-véronique Joubert, Céline Mazzotti, Anaïs Schavgoulidze, Stéphane Minvielle, Philippe Moreau, Cyrille Touzeau, Herve Avet-Loiseau, Aurore Perrot, Jill Corre, Ludovic Martinet

Blood (2025) 146 (Supplement 1): 3932.

https://doi.org/10.1182/blood-2025-3932

Published: 2025

Journal Articles

Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)

Blood (2025) 146 (Supplement 1): 2275.

https://doi.org/10.1182/blood-2025-2275

Published: 2025

Journal Articles

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Enrique Ocio, Aurore Perrot, Jesus San-Miguel, Lionel Karlin, Joaquin Martinez-Lopez, Sara Bringhen, Paula Rodriguez-Otero, Mohamad Mohty, Robert Orlowski, Meletios Dimopoulos, Xavier Leleu, María-Victoria Mateos, Philippe Moreau, Sandrine Macé, Ecrem Kodas, Christine Tekle, Umer Khan, Corina Oprea, Thierry Facon

Blood (2025) 146 (Supplement 1): 2267.

https://doi.org/10.1182/blood-2025-2267

Published: 2025

Journal Articles

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Blood (2025) 146 (Supplement 1): 372.

https://doi.org/10.1182/blood-2025-372

Published: 2025

Journal Articles

Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)

Blood (2025) 146 (Supplement 1): 368.

https://doi.org/10.1182/blood-2025-368

Published: 2025

Journal Articles

A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a

Blood (2025) 146 (Supplement 1): 367.

https://doi.org/10.1182/blood-2025-367

Published: 2025

Journal Articles

Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.

Blood (2025) 146 (Supplement 1): 364.

https://doi.org/10.1182/blood-2025-364

Published: 2025

Journal Articles

Favorable impact of patient's selection on outcome of Relapsed/Refractory multiple myeloma treated with idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy; Experience in french patients (Super-FENIX): An IFM study from the descar-T registry

Blood (2025) 146 (Supplement 1): 4076.

https://doi.org/10.1182/blood-2025-4076

Published: 2025

Journal Articles

Patient perspectives and preferences for step-up dosing and treatment with teclistamab and talquetamab: Insights from a patient survey

Jay Hydren, Rachel Jensen, Jorge Arturo Hurtado Martinez, Jennifer Ahlstrom, Mason Barnes, Caitlin Costello, Gurbakhash Kaur, Meera Mohan, Francesca Cottini, Douglas Sborov, Shaji Kumar, Noopur Raje, Philippe Moreau, Maithili Deshpande, Niodita Gupta-Werner, Tonya Le Blanc, Jessica Fowler, Rahul Banerjee

Blood (2025) 146 (Supplement 1): 6354.

https://doi.org/10.1182/blood-2025-6354

Published: 2025

Journal Articles

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone

Blood blood.2025030113.

https://doi.org/10.1182/blood.2025030113

Published: 2025

Includes: Supplemental data

Journal Articles

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

Blood (2025) 146 (6): 679–692.

https://doi.org/10.1182/blood.2024027620

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load

A T-cell–based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy

A comparison between subcutaneous isa-vrd from the isasocut study and intravenous isa-vrd from the imroz study in patients with transplant- ineligible newly diagnosed multiple myeloma

Relative mortality in elderly frail patients with newly diagnosed multiple myeloma: Ad-hoc analysis of the Phase 3 IFM 2017-03 trial compared to population-based data in France and implications for the functional cure concept

Longitudinal assessments of minimal residual disease in high-risk patients from benefit phase 3 randomized Study of isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isard in newly diagnosed transplant ineligible multiple myeloma. (IFM 2020-05)

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.

Apixaban pharmacokinetics in newly diagnosed multiple myeloma patients treated in the benefit and isasocut clinical trials: The apixabor/mibapix study

Single-cell immune landscape associated with isatuximab, carfilzomib, lenalidomide, and dexamethasone induction efficacy in newly diagnosed myeloma

Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)

A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a

Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.

Favorable impact of patient's selection on outcome of Relapsed/Refractory multiple myeloma treated with idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy; Experience in french patients (Super-FENIX): An IFM study from the descar-T registry

Patient perspectives and preferences for step-up dosing and treatment with teclistamab and talquetamab: Insights from a patient survey

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only